Calcific uremic arteriolopathy – treatment with sodium thiosulfate

Czech version

Authors: Markéta Vyskočilová; Jan Svojanovský; Jana Blaštíková; Gabriela Dvořáková; Miroslav Souček
Authors‘ workplace: II. interní klinika LF MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.
Published in: Vnitř Lék 2015; 61(2): 166-172
Category: Case Report

Overview

Calcific uremic arteriolopathy or calciphylaxis is a rare disorder characterized by systemic medial calcification of arterioles that leads to ischemia and subcutaneous necrosis. It most commonly occurs in patients with end-stage renal disease who are on haemodialysis or who have received a renal transplant. Calciphylaxis is dangerous by its fast progression into tissue necrosis, difficult healing process and a great risk of secondary infection which is the most common cause of death in this condition. The reported mortality rates are as high as 60–80 % in a couple of months once it is diagnosed. The key to successful treatment of calciphylaxis is fast diagnosing of the disease and appropriate treatment management. On the examples of three patients from our haemodialysis centre we demonstrate typical clinical manifestation of calciphylaxis and its treatment, which requires close patient-medical staff cooperation. The basic principle of treatment of all our patients was normalization of calcium-phosphate metabolism and secondary hyperparathyroidism. Sodium thiosulfate had been administered to all patients at the end of haemodialysis session. The wound care played another major role with gentle debridement and intensive local care. After five to six months the skin defects resolved in the first patient, partially resolved in the second patient and deteriorated in the third patient. We have observed no side effects of sodium thiosulfate application.

Key words:
calcific uremic arteriolopathy – calciphylaxis – haemodialysis – sodium thiosulfate

Sources

1. Herout V, Ryska A, Pohnetalova D et al. Kalcifylaxe u dlouhodobě dialyzované nemocné. Vnitř Lék 1997; 43(11): 753–755.

2. Hájková B. Kalcifylaxe – popis případu a rozbor problematiky. Aktuality v nefrologii 2009; 15(4): 169–171.

3. Selye H, Gentile G, Prioreschi P. Cutaneous molt induced by calciphylaxis in the rat. Science 1961; 134(3493): 1876–1877.

4. Anderson DC, Stewart WK, Piercy DM. Calcifying panniculitis with fat and skin necrosis in a case of uremia with autonomous hyperparathyroidism. Lancet 1968; 2(7563): 323–325.

5. Teplan V et al. Praktická nefrologie. 2nd ed. Grada: Praha 2006: 102. ISBN 80–247–1122–2.

6. Sulková S (ed). Hemodialýza. Maxdorf: Praha 2000: 462–463. ISBN 80–85912–22–8.

7. Mason D, Best SD. Calcific uremic arteriolopathy: contemporary pharmacotherapy. Adv Chronic Kidney Dis 2010; 17(5): 428–438.

8. Cinone J, Petronis J, Embert C et al. Successful treatement of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43(6): 1104–1108.

9. Brucculeri M, Cheigh J, Bauer G et al. Long-term intravenous sodium thiosulfate in the treatement of a patient with calciphylaxis. Semin Dial 2005; 18(5): 431–434.

10. Auriemma M, Carbone A, Di Libetaro L. Treatement of cutaneous calciphylaxis with sodium thiosulfate. AM J Clin Dermatol 2011; 12(5): 339–346.

11. Vyskočilová M. Kalcifikující uremická arteriolopatie – kazuistika – zkušenosti našeho pracoviště. In: XXXI. dni mladých internistov s medzinárodnou účasťou. Martin, Slovenská republika, 24.-25.5.2012 (Abstrakta). Dostupné z WWW: <http://www.vnitrnilekarstvi.eu/online/E2012_7>.

12. Blaštíková J, Svojanovský J, Souček M. Kalcifikující uremická arteriolopatie. Poster. 34. Kongres České nefrologické společnosti s mezinárodní účastí. Brno, 14.-16.6.2012.

13. Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 2008; 17(6): 629–634.

14. Angelis M, Wong LL, Myers SA et al. Calciphylaxis in patients on haemodialysis: a prevalence study. Surgery 1997; 122(6): 1083–1089.

15. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61(6): 2210–2217.

16. Mazhar AR, Johnson RJ, Gillen D et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60(1): 324–332.

17. Hafner J, Keusch G, Wahl C et al. Calciphylaxis: A syndrome of skin necrosis and acral gangrene in chronic renal failure. Vasa 1998; 27(3): 137–143.

18. Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol 1996; 7(7): 978–782.

19. Sobotová D. Chronické onemocnění ledvin. In: Souček M, Špinar J, Vorlíček J (eds). Vnitřní lékařství. Grada: Praha 2011. ISBN 978–80–247–2110–1.

20. Hafner J, Keusch G, Wahl C et al. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): A complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 1995; 33(6): 954–962.

21. Bleyer AJ, Choi M, Igwemezie B et al. A case control study of proximal calciphylaxis. Am J Kidney Dis 1998; 32(3): 376–383.

22. Weening RH, Sewell LD, Davis MD et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007; 56(4): 569–579.

23. Hayashi M, Takamatsu I, Kanno Y et al. A case-control study of calciphylaxis in Japanese end-stage renal dinase patiens. Nephrol Dial Transplant 2012; 27(4): 1580–1584.

24. Lebreton JP, Joisel F, Raoult JP et al. Serum concentration of human alpha 2 HS glykoprotein during the inflammatory process: evidence that alpha 2 HS glykoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64(4): 1118.

25. Šafránek R. Kalcifylaxe. Postgraduální nefrologie 2011; 9(2): 29.

26. Girotto JA, Harmon JW, Ratner LE et al. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery 2001; 130(4): 645–650.

27. Risikofaktoren & Therapieansätze: Behandlungsansätze der Calciphylaxie. Dostupné z WWW: <http://www.calciphylaxis.net/index.php?id=325&L=0>.

28. Pasch A, Schaffner T, Huynh-Do U et al. Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int 2008; 74(11): 1444–1453.

29. O´Neil WC, Hardcastle KI. The chemistry of thiosulfate and vascular calcification. Nephrol Dial Transplant 2012; 27(2): 521–526.

30. Hayden MR, Goldsmith D, Sowers JR et al. Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol 2008; 40(2): 443–451.

31. Cicone JS, Petronis JB, Embert CD et al. Successful management of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43(6): 1104–1108.

32. Brucculeri M, Cheigh J, Bauer G et al. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial 2005; 18(5): 431–434.

33. Hayden MR. Calciphylaxis and the cardiometabolic syndrome: the emerging role of sodium thiosulfate as a novel treatement option. J Cardiometab Syndr 2008; 3(1): 55–59.

34. Hayden MR, Tyagi SC, Kolb L et al. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005; 4: 4. Dostupné z DOI: <http:// 10.1186/1475–2840–4-4>.

35. Nigwekar SU, Brunelli SM, Meade D et al. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol 2013; 8(7): 1162–1170.

36. Brandenburg V. Kommentar zu: Sodium Thiosulfate Therapy for Calcific Uremic Arteriolopathy von Sagar Nigwekar und Kollegen, Massachusetts General Hospital Boston, in CJASN online Mai 2013. Dostupné z WWW: <http://www.calciphylaxie.de>.

37. Sowers KM, Hayden MR Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev 2010; 3(2): 109–121.

38. Pennanen N, Lapinjoki S, Urtti A et al. Effect of liposomal and free bisphosphonates on IL-1 beta, IL-6 and TNFalpha secretion from RAW 264 cells in vitro. Pharm Res 1995; 12(6): 916–922.

39. Sulková Dusilová S, Válek M. Skin wounds associated with calciphylaxis in end-stage renal disease patients on dialysis. Nutrition 2010; 26(9): 910–914.

40. Brandenburg VM, Kramann R, Specht P et al. Calciphylaxis in CKD and beyond. Nephrol Dial Transplant 2012; 27(4): 1314–1318.